Who Paid My Doc
Armen Avetisyan
Nurse Practitioner, Family Glendale, CA Nurse Practitioner
NPI 1972909406 CMS profile 11095244
1030 S Glendale Ave Ste 404, Glendale, CA 91205
General payments
$890
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Armen Avetisyan of Glendale, CA is reported in the CMS Open Payments database as having received $890 across 35 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 69th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $474 | 21 | |
| 2024 | General | $31 | 1 | |
| 2023 | General | $179 | 2 | |
| 2022 | General | $33 | 1 | |
| 2021 | General | $174 | 10 |
Beside peers
- Armen Avetisyan
- Nurse Practitioner, Family median
- Middle half of Nurse Practitioner, Family
- National median
In program year 2025, general payments to Armen Avetisyan were reported at $474. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.
Show as a table
| Year | Armen Avetisyan | Nurse Practitioner, Family median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $39 | $18–$91 | $163 |
| 2020 | $0 | $32 | $17–$76 | $114 |
| 2021 | $174 | $124 | $35–$379 | $132 |
| 2022 | $33 | $141 | $44–$430 | $149 |
| 2023 | $179 | $154 | $49–$476 | $160 |
| 2024 | $31 | $165 | $51–$504 | $164 |
| 2025 | $474 | $168 | $53–$521 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 250 drugsPart D claims
23,144
Drug cost
$2,887,032
Branded share of claims
24.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Omeprazole-Sodium Bicarbonate Omeprazole/Sodium Bicarbonate | Brand | 341 | $500,218 | |
| Metformin Er Gastric Metformin Hcl | Brand | 124 | $282,160 | |
| Diclofenac Sodium | Generic | 464 | $198,931 | |
| Linzess Linaclotide | Brand | 264 | $151,780 | |
| Vascepa Icosapent Ethyl | Brand | 402 | $134,650 | |
| Creon Lipase/Protease/Amylase | Brand | 105 | $106,348 | |
| Januvia Sitagliptin Phosphate | Brand | 169 | $104,828 | |
| Tavaborole | Generic | 64 | $83,654 | |
| Jardiance Empagliflozin | Brand | 127 | $80,468 | |
| Chlorzoxazone | Generic | 51 | $69,410 |
The 10 drugs with the highest cost, of 250 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 69 billing codesPaid by Medicare
$128,924
Medicare patients
375
Services billed
6,500
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 75% | |
| Arthritis | 75% | |
| Diabetes | 53% | |
| Depression | 39% | |
| Alzheimer's or dementia | 36% | |
| COPD | 32% | |
| Osteoporosis | 31% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, onabotulinumtoxina, 1 unit J0585 | Office | 18 | 1,070 | $5,333 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 113 | 2,224 | $1,723 |
| Vaccine for influenza for injection into muscle 90662 | Office | 11 | 11 | $671 |
| Injection, ketorolac tromethamine, per 15 mg J1885 | Office | 33 | 117 | $52 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 83 | 404 | $36 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 | Office | 31 | 38 | $33 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
35 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Nurse Practitioner, Family in California
Lori Robertson
Nurse Practitioner, Family · Chino Hills, CA
Annette Shon
Nurse Practitioner, Family · Los Angeles, CA
Lisa Higgins
Nurse Practitioner, Family · Hanford, CA
Jennifer Tougas
Nurse Practitioner, Family · Bakersfield, CA
Kim Schafer
Nurse Practitioner, Family · Sacramento, CA
Dawn Meyer
Nurse Practitioner, Family · San Diego, CA
Related records
Nurse Practitioner, Family in California
Practitioners in the same specialty and state, ranked by reported value.
All Nurse Practitioner, Family
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.